Pam2CSK4 TFA 是一种 TLR2 激动剂,通过 TBK1 和 MyD88 分子在巨噬细胞系中诱导 iNOS 和 NO 表达,激活血小板 NF-kB 和布罗顿酪氨酸激酶信号通路以促进血小板-内皮细胞相互作用,其触发的 TLR2 激活会增强髓系来源的抑制性细胞 (MDSCs) 并在肿瘤微环境中抑制抗肿瘤免疫反应,同时在硕大利什曼原虫和马来布鲁线虫小鼠疫苗模型中作为一种 Th2 极化佐剂,可用于血栓炎症性疾病、脓毒症、动脉粥样硬化、心力衰竭、流感、淋巴瘤、黑色素瘤、皮肤利什曼病和淋巴丝虫病等多种疾病的研究。
Pam2CSK4 TFA
产品编号: MS-K49146 纯度: 99.46% 分子式: C65H126N10O12S.xC2Hf3O2 分子量: 1271.82 (free base)
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
询价
10mg
询价
询价
50mg
询价
询价

产品描述

Pam2CSK4 TFA 是一种 TLR2 激动剂,通过 TBK1 和 MyD88 分子在巨噬细胞系中诱导 iNOS 和 NO 表达,激活血小板 NF-kB 和布罗顿酪氨酸激酶信号通路以促进血小板-内皮细胞相互作用,其触发的 TLR2 激活会增强髓系来源的抑制性细胞 (MDSCs) 并在肿瘤微环境中抑制抗肿瘤免疫反应,同时在硕大利什曼原虫和马来布鲁线虫小鼠疫苗模型中作为一种 Th2 极化佐剂,可用于血栓炎症性疾病、脓毒症、动脉粥样硬化、心力衰竭、流感、淋巴瘤、黑色素瘤、皮肤利什曼病和淋巴丝虫病等多种疾病的研究。

生物实验数据

生物活性 Pam2CSK4 TFA is a TLR2 agonist that induces iNOS and NO expression in macrophage cell lines through TBK1 and MyD88 molecules, activates platelet NF-kB and Bruton's tyrosine kinase signaling pathways to promote platelet-endothelial cell interactions, and its triggered TLR2 activation enhances myeloid-derived suppressor cells (MDSCs) and suppresses antitumor immune responses in the tumor microenvironment; it serves as a Th2-polarizing adjuvant in mouse vaccine models of Leishmania major and Brugia malayi, and can be used for research on various diseases including thromboinflammatory diseases, sepsis, atherosclerosis, heart failure, influenza, lymphoma, melanoma, cutaneous leishmaniasis, and lymphatic filariasis.
体外研究
(In Vitro)

Pam2CSK4 (100 ng/mL; 6-24 h) TFA 可诱导 RAW264.7 小鼠巨噬细胞中由 TLR2 介导的 iNOS 表达,这种生成依赖于 TBK1、MyD88。
Pam2CSK4 (100 ng/mL; 6-24 h) TFA 可在 RAW264.7 小鼠巨噬细胞中诱导由 TLR2 介导显著的 NO 生成,这种生成依赖于 TBK1、MyD88。
Pam2CSK4 (1-10 μg/mL; 25 min at 37°C) TFA 可在洗涤后的人血小板和枸橼酸化人全血中血小板中诱导浓度依赖性的 α-颗粒分泌及整合素 αIIbβ3 激活。
Pam2CSK4 (10 μg/mL; 6-45 min at 37°C) TFA 可在搅拌条件下诱导洗涤后人血小板发生供体依赖性聚集,增强洗涤后的人血小板在胶原包被表面的黏附作用。
Pam2CSK4 (10 μg/mL; 2-10 min at 37°C) TFA 可激活洗涤后人血小板中的多条信号通路,包括 Akt、PKC、NF-κB 和 MAPK (p38) 通路。
Pam2CSK4 (10 μg/mL) TFA 可诱导洗涤后的人血小板发生致密颗粒分泌 (ATP 释放),且该反应依赖于 TLR2、NF-κB 和 BTK 信号通路。
Pam2CSK4 (10 μg/mL; 4 h at 37°C) TFA 仅在与洗涤后的人血小板共培养时,才会增强 HUVEC 的炎症反应 (表现为 ICAM-1 表达上调、IL-6 分泌增加及 IL-8 分泌增加)。
Pam2CSK4 (10 μg/mL; 10 min at 37°C platelet pre-incubation, 10 min co-culture) TFA 可在静态条件和生理相关流动条件下增强洗涤后人血小板对未处理及经 TNF-α 刺激的 HUVEC 单层细胞的黏附作用。
Pam2CSK4 TFA 是一种强效的人源与鼠源双重 TLR2 激动剂,可诱导 NF-κB 活性,其 EC50 为 67 pM,并能诱导产生多种细胞因子和趋化因子。
Pam2CSK4 (100 nM; 3 days) TFA 处理的荷 EG7 瘤小鼠来源 CD11b+Gr1+ 髓系来源抑制性细胞 (MDSCs) 可呈剂量依赖性抑制抗原诱导的 OT-I T 细胞增殖。

RT-PCR

Cell Line: RAW264.7
Concentration: 100 ng/mL
Incubation Time: 6 h
Result: Induced detectable inos gene expression.
Induced inos gene expression that was suppressed by pretreatment with TLR2 neutralizing monoclonal antibody.

Western Blot Analysis

Cell Line: RAW264.7
Concentration: 100 ng/mL
Incubation Time: 10 h
Result: Induced detectable iNOS protein expression.
Induced iNOS protein expression that was suppressed by pretreatment with TLR2 neutralizing monoclonal antibody.

Western Blot Analysis

Cell Line: Washed platelets
Concentration: 10 μg/mL
Incubation Time: 2, 5, 10 min
Result: Significantly increased tyrosine phosphorylation, increased 4G10 antibody expression.
Increased phosphorylation levels at Akt S473 and downstream substrates.
Increased phosphorylation levels of MAPK substrates and p38 T180Y182.
体内研究
(In Vivo)

Pam2CSK4 (50 nM; i.v.; single dose) TFA 可在荷 EG7 肿瘤小鼠中诱导依赖 TLR2 的系统性免疫抑制性 CD11b+Gr1+ MDSC 聚集,并提升 MDSC 的存活率。
Pam2CSK4 (50 nM; i.v.; single dose) TFA 可在荷 B16D8 黑色素瘤小鼠的脾脏中诱导 CD11b+Gr1+ MDSCs 聚集。
Pam2CSK4 (10 μg; s.c.; two doses, 2 weeks apart) TFA 作为与硕大利什曼原虫 (ALM) 联合的佐剂,会加重雌性 C57BL/6 小鼠的皮肤利什曼病病情严重程度,并诱导以抗原特异性 IgG1 水平升高为特征的以 Th2 型为主的免疫应答。
Pam2CSK4 (10 μg; s.c.; single dose) TFA 作为搭配马来布鲁线虫微丝蚴寄生虫提取物 (BmMfE) 的佐剂,可在雄性 BALB/c 小鼠中诱导针对 B. malayi L3 攻击的保护性免疫,使寄生虫负荷降低 41%,并驱动 Th2 细胞因子产生及抗原特异性抗体应答。

Animal Model: C57BL/6J (B6 WT) female mice (8-12 weeks old); TLR2 knockout (TLR2KO) female mice (8-12 weeks old); C57BL6-Tg (CAG-EGFP) female mice (8-12 weeks old) EG7 cells (1x106)
Dosage: 50 nM
Administration: i.v.; single dose
Result: Increased the proportion of CD11b+Gr1+ myeloid-derived suppressor cells (MDSCs) in CD45+ splenocytes to 12.9%.
Increased the proportion of CD11b+Gr1+ MDSCs in peripheral blood CD45+ cells to approximately 50%.
Increased the proportion of CD11b+Gr1+ MDSCs in tumor-bearing GFP+CD45+ host cells to approximately 27%.
Eliminated the increased proportion of CD11b+Gr1+ MDSCs in TLR2KO EG7 tumor-bearing mice.
Induced dose-dependent inhibition of OT-I splenocyte proliferation by CD11b+Gr1+ cells in tumor-bearing mice.
Animal Model: C57BL/6J (B6 WT) female mice (8-12 weeks old) ( B16D8 (6x105)
Dosage: 50 nM
Administration: i.v.; single dose
Result: Increased the percentage of CD11b+Gr1+ MDSCs in CD45+ spleen cells to 21.1%.
Animal Model: C57BL/6 (female, 8-10 weeks old; vaccinated with autoclaved Leishmania major then challenged with L. major metacyclic promastigotes)
Dosage: 10 μg
Administration: s.c.; two doses, 2 weeks apart
Result: Increased lesion sizes significantly compared to PBS-vaccinated control mice from 4 weeks post-infection, with significantly increased area under the curve (AUC) values for lesion progression.
Elevated antigen-specific IgG1 responses significantly compared to PBS-vaccinated controls, and skewed the IgG1:IgG2c ratio toward a Th2 phenotype.
Animal Model: BALB/c (male, 8-10 weeks old; vaccinated with Brugia malayi microfilariae extract then challenged with B. malayi L3 larvae)
Dosage: 10 μg
Administration: s.c.; single dose
Result: Reduced parasite recovery by a significant mean 41%, equivalent to the protection induced by BmMfE + Alum.
Elevated antigen-specific IgG1 and IgG2a levels significantly, with IgG1 levels higher than those induced by BmMfE + Alum.
Induced significantly elevated production of antigen-specific IL-4, IL-5, and IL-13 (Th2 cytokines) in splenocytes upon re-stimulation with B.
malayi L3 extract, with no significant elevation of the Th1 cytokine IFNγ.
性状 固体
颜色 White to off-white

化学信息

分子量 1271.82 (free base)
分子式 C65H126N10O12S.xC2Hf3O2

储存&溶解度

储存方式

Sealed storage, away from moisture and light

Powder -80°C 2 years
-20°C 1 year

*In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础